Topline results from the Phase IIIa FRONTIER 2 trial show a positive treatment effect for Novo Nordisk’s (NOV: N) hemophilia A treatment Mim8. 14 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financ 14 May 2024
Oncology companies including New York-based giant Pfizer (NYSE: PFE) and Japan’s Astellas Pharma (TSE: 4503) have outlined details of data they intend to presen 13 May 2024
Boston-based genomic medicines company Ensoma has announced the appointment of Jim Burns as chief executive and a member of the board of directors. 13 May 2024
Immuno-oncology company iTeos Therapeutics has lofty ambitions, claiming to be pioneering the discovery and development of a new generation of highly differenti 13 May 2024
Despite a lower dose, data from the Phase II stage of the TAMARACK study have raised concerns over the safety profile of MacroGenics’ antibody-drug conjugate (A 13 May 2024
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, 13 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.